-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The COVID-19 vaccine Comirnaty (BNT162b2) jointly developed by Pfizer/BioNTech was granted emergency use authorization by the FDA only 221 days after the first human clinical trial (FIH) in the United States, which can be called the "speed of light" for drug developme.
However, Pfizer has been equally good at getting new drugs to market at the same time as major regulatory agencies around the world:
However, Pfizer has been equally good at getting new drugs to market at the same time as major regulatory agencies around the world:On April 11 this year, the National Medical Products Administration (NMPA) approved Pfizer’s Class 1 innovative drug abrucitinib (trade name: Cibinqo) through the priority review and approval proce.
Originally, it was not surprising that the products of multinational pharmaceutical companies were approved in China, but ••••••
On September 8, 2021, Cibinqo was approved by the Medicines and Health Products Regulatory Agency (MHRA) in the .
On September 27, 2021, Cibinqo was approved by the Japanese Ministry of Health, Labour and Welfare (MHL.
On December 9, 2021, Cibinqo was approved by the European Medicines Agency (EM.
On January 14, 2022, Cibinqo was approved by the.
It only took Pfizer about 7 months to complete the approval and listing of Cibinqo in the five major global pharmaceutical markets of the United Kingdom, Japan, the European Union, the United States and Chi.
It only took Pfizer about 7 months to complete the approval and listing of Cibinqo in the five major global pharmaceutical markets of the United Kingdom, Japan, the European Union, the United States and Chi.
In recent years, global pharmaceutical giants represented by Pfizer have accelerated the development of new drugs and simultaneous listing in the global mark.
